Pre-Conference Workshop Day

Tuesday July 18, 2023 | 9am - 2:30pm

Workshop A 8.30

8:30 am Deciphering the Complexities of the Tumor Microenvironment to Unravel Myeloid Cell Dynamics

  • Nagy Habib Professor of Surgery, Imperial College London


The tumor microenvironment consists of a diverse array of innate immune cells that engage in intricate interactions among themselves and with tumor cells. This engaging workshop is designed to provide participants with a comprehensive understanding of the intricate interactions between the TME and myeloid cells, with a focus on unraveling the dynamic influences shaping immune responses.

Join this Workshop to gain an overview of the importance of TME and myeloid cells in cancer biology:

  • Discussion on the dynamic nature of the TME and its impact on cancer progression
  • Discussion on the dual role of myeloid cells in both promoting and inhibiting tumor growth
  • Examination of specific molecular pathways and signalling mechanisms involved in TME-myeloid cell crosstalk

10:30 am Morning Refreshment Break

Workshop B 11.00

11:00 am Precise Strategies to Uncover Biomarkers & Endpoints for Myeloid Cell Therapies

  • Ananta Paine Precision Medicine | Biomarker | Preclinical and Clinical Studies | Cross-functional Leadership, Boston University


Biomarkers are often cheaper and easier to measure than ‘true’ endpoints. This workshop is designed to provide participants with comprehensive insights into the crucial process of selecting effective biomarkers and subsequent endpoints for measuring the full effect of myeloid therapies. Attendees will gain a deep understanding of the significance of biomarker selection in monitoring therapeutic outcomes and identifying relevant endpoints to assess the efficacy of myeloid cell-based interventions.

Join this workshop to:

  • Discuss criteria for selecting effective biomarkers, including sensitivity, specificity, and feasibility
  • Review real-world case studies highlighting successful biomarker selection for myeloid cell therapies
  • Understand the relationship between selected biomarkers and clinically relevant endpoints and how they align with therapeutic goals and patient outcomes
  • Gain an overview of regulatory requirements for biomarker and endpoint selection in myeloid cell therapy trials

1:00 pm Lunch & Networking

Workshop C

2:00 pm What To Expect:


Monotherapies have been promoted as the ideal in treatments due to reduced side effects, minimized drug resistance, better compliance and overall lower cost, whereas combining existing therapeutic approaches, particularly synergizing therapies, is emphasized for more effective results in targeting myeloid cells within the tumor microenvironment.

This discussion led workshop delves into case study examples by TME Pharma and Bolt Biotherapeutics of both combination and monotherapies involving myeloid cells. Join this Workshop to gain insights into diverse approaches that harness the synergistic potential of myeloid cell therapies

2:00 pm TME Pharma Case Study – Combination


  • Overview of the rationale behind exploring combination strategies at TME Pharma
  • Importance of synergistic approaches in maximizing the effectiveness of myeloid cell interventions
  • Exploration of various combination strategies involving myeloid cells, including Myeloid cell therapy combined with immunotherapies, combination with traditional cancer treatments (chemotherapy, radiation), integrating myeloid cell therapies with targeted therapies
  • Exploration of emerging trends and innovative strategies in combining myeloid cell therapies
  • Addressing regulatory considerations and challenges in translating combination therapies from bench to bedside

3:00 pm Bolt Biotherapeutics Case Study – Monotherapy

  • Michael Alonso Vice President - Immunology & Pharmacology, Bolt Biotherapeutics


  • Overview of the rationale behind exploring combination strategies at Bolt Biotherapeutics
  • Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment
  • BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer
  • Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics